Endoscopic Gastric Sleeve (ESG): Surgery, Mechanism, and Alternatives

Endoscopic sleeve gastroplasty (ESG) has gained visibility as a non-surgical approach to weight loss. It can be appealing to patients who want meaningful results without the commitment of an operation. The absence of incisions and the shorter recovery window make it an accessible option on paper. 

In clinical practice, however, ESG is a restrictive procedure with no metabolic mechanism, and its outcomes fall considerably short of surgical bariatric procedures in both magnitude and durability. Many high-volume bariatric programs do not offer it as a primary weight loss solution for this reason. Understanding what ESG actually does and what it does not do is essential before comparing it to gastric sleeve surgery or other forms of bariatric surgery.

Endoscopic gastric sleeve, also called endoscopic sleeve gastroplasty, is a minimally invasive weight loss procedure performed entirely through the mouth using a flexible endoscope. No external incisions are made. The endoscope carries a suturing device that places a series of full-thickness sutures through the interior of the stomach wall, folding and cinching the stomach into a smaller, tubular shape.

The critical distinction from surgical sleeve gastrectomy is that no tissue is removed. The stomach is not resected, it is compressed. The original anatomy remains structurally intact beneath the sutures, which has direct implications for how long the restriction holds and how the body responds metabolically. ESG is classified as an endoscopic bariatric therapy, not a surgical procedure, and is performed under sedation rather than general anesthesia in most settings.

ESG reduces stomach volume through internal sutures that fold the greater curvature inward, creating a narrower gastric lumen. This smaller volume limits the amount of food that can be consumed at one sitting and slows gastric emptying, which prolongs fullness after meals.

The mechanism is purely restrictive. ESG does not alter gut hormone secretion in the way that surgical bariatric procedures do. Ghrelin (the primary hunger-stimulating hormone produced in the gastric fundus)  is not removed or significantly suppressed, because the fundus is folded rather than excised. GLP-1 secretion, insulin sensitivity, and other metabolic signaling pathways associated with weight regulation are not meaningfully engaged by the procedure.

This is the central difference between metabolic and restrictive weight loss procedures. Surgical options like gastric sleeve and gastric bypass achieve weight loss through a combination of restriction and hormonal change. ESG achieves it through restriction alone, which places the entire burden of long-term outcomes on dietary adherence and behavioral change.

Clinical studies report average total body weight loss of 15–20% at one to two years following ESG, with significant variation across patient populations. Some patients achieve results toward the higher end of that range; others see considerably less, particularly those who do not make concurrent dietary changes.

For patients with moderate obesity and no significant metabolic disease, these results may be sufficient. For patients dealing with severe obesity, type 2 diabetes, or other metabolic comorbidities, ESG’s weight loss range is unlikely to produce the clinical improvements that surgical procedures reliably achieve.

ESG and surgical sleeve gastrectomy share a similar shape in imaging, but the two procedures differ fundamentally in mechanism, durability, and metabolic effect.

Surgical sleeve gastrectomy removes approximately 80% of the stomach, the primary site of ghrelin production. ESG folds the stomach using sutures without removing any tissue. The stomach volume is reduced, but the underlying anatomy is preserved and remains capable of expanding if sutures loosen over time.

Surgical sleeve gastrectomy triggers significant changes in gut hormone signaling. Ghrelin levels fall substantially after surgery, reducing baseline hunger. GLP-1 secretion increases, improving insulin sensitivity and supporting glycemic regulation. ESG does not drive these hormonal changes. Because the fundus is not removed, ghrelin suppression does not occur to a clinically meaningful degree.

Sutures placed endoscopically are subject to loosening over time, particularly under the mechanical stress of eating. As sutures weaken, the stomach can partially return toward its original shape. A structural limitation that does not apply to surgical sleeve gastrectomy, where the resected tissue is permanently removed. Long-term outcome data for ESG beyond three to five years remains limited compared to the extensive evidence base supporting surgical procedures.

Many bariatric surgeons evaluate procedures by a consistent standard: does this intervention provide durable weight loss, metabolic improvement, and long-term disease control? By that measure, ESG occupies a limited position in the clinical hierarchy.

High-volume bariatric programs tend to focus on procedures with established metabolic mechanisms and long follow-up data. Surgical sleeve gastrectomy has decades of outcome evidence and a well-characterized hormonal effect. Gastric bypass adds malabsorption to restriction and hormonal change, producing stronger and more consistent results for metabolic disease. Advanced procedures including transit bipartition and SADI-S extend these metabolic benefits further.

Procedure	Type	Average Weight Loss	Hormonal Effect
Endoscopic Gastric Sleeve	Endoscopic	15–20% TBWL	Minimal
Gastric Sleeve	Surgical	25–30% TBWL	Significant
Gastric Bypass	Surgical	30–35% TBWL	Strong

From this clinical perspective, ESG’s limited hormonal engagement and moderate weight loss ceiling lead many experienced surgeons to view it as appropriate only for a narrow patient profile.

ESG is considered minimally invasive, but the stomach wall is actively manipulated during the procedure, and complications can occur. Patients should understand the risk profile before choosing ESG on the assumption that it carries no meaningful procedural risk.

• Bleeding: Suturing through the full thickness of the stomach wall carries a risk of intraluminal or extraluminal bleeding, which may require endoscopic or surgical intervention in rare cases.
• Stomach perforation: Inadvertent perforation of the gastric wall during suture placement is an uncommon but serious complication requiring urgent management.
• Suture failure: Individual sutures may tear through the stomach tissue over time, particularly in patients who return to large-volume eating. Failure of multiple sutures diminishes restriction and may necessitate a repeat procedure.
• Nausea and abdominal pain: The most common post-procedure complaints. These are expected in the early recovery period and resolve in most patients within days to weeks.
• Need for repeat procedures: As sutures loosen and restriction diminishes, some patients undergo a second ESG to restore the initial stomach volume reduction, adding procedural risk and cost to the long-term equation.

ESG is most appropriate for patients with a BMI in the range of 30–40 who prefer to avoid surgery, are not candidates for surgical intervention due to anesthetic or medical risk, or are seeking a time-limited intervention before committing to a definitive surgical procedure.

Patients who respond best are those who pair the procedure with structured dietary coaching, behavioral support, and realistic expectations about the degree of weight loss ESG can achieve independently.

For patients with a BMI above 40, obesity-related metabolic disease, or a history of weight regain after previous interventions, surgical bariatric procedures offer more reliable long-term outcomes. The hormonal and metabolic mechanisms engaged by surgery address the physiological drivers of obesity in ways that endoscopic restriction alone cannot replicate.